Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind, Placebo-Controlled, Two-Period Crossover, Phase 2 Clinical Trial to Evaluate the Safety, Tolerability, and Efficacy of ADX-629 Administered Orally to Subjects With Chronic Cough

Next Previous
Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Two-Period Crossover, Phase 2 Clinical Trial to Evaluate the Safety, Tolerability, and Efficacy of ADX-629 Administered Orally to Subjects With Chronic Cough

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 02 Mar 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ADX-629 (Primary)
  • Indications Cough
  • Focus Adverse reactions
  • Sponsors Aldeyra Therapeutics

Most Recent Events

  • 27 Jun 2023 Status changed from active, no longer recruiting to completed.
  • 26 Jun 2023 According to an Aldeyra Therapeutics media release, the company announced it will host a webcast and conference call on Tuesday, June 27, 2023, at 8:00 a.m. (ET) to provide top-line results from the Phase 2 clinical trial of ADX-629 in patients with chronic cough, A live audio webcast of the conference call also will be accessible from the Investors & Media section of Aldeyras website at ir.aldeyra.com. After the live webcast, the event will remain archived on Aldeyras website for 90 days.
  • 04 May 2023 According to an Aldeyra Therapeutics media release, Top-Line results from this trial are expected in the second quarter of 2023.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top